Rothschild & Co Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $140

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE

0.00

Rothschild & Co analyst Qize Ding initiates coverage on Apogee Therapeutics (NASDAQ: APGE) with a Buy rating and announces Price Target of $140.